Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 10, 2013

Nuvo Scores $2M Payment from Galderma for Launch of Topical Anesthetic in Brazil

  • Following launches in the U.S. and European Union earlier this year, Nuvo Research and its licensing partner Galderma announced that Pliaglis, a topical local anesthetic, has been approved for sale and marketing in Brazil and is expected to launch in early 2014. Nuvo will receive a $2 million payment from Galderma for attaining this milestone.

    Pliaglis uses Nuvo’s phase-changing technology to form a pliable peel on the skin when exposed to air. According to the company, Pliaglis is indicated for use on intact skin in adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.

    The original promotion and distribution agreement for Pliaglis was inked in 2008 between ZARS Pharma and Galderma. Nuvo acquired ZARS two years ago.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »